Abstract 4024: Cancer research advocates: satisfaction, frustration, and opportunities

Abstract Introduction: Advocates have been involved in cancer research for several decades, but little is known about their opinions regarding what is satisfying and what is frustrating. This largely qualitative study gathered feedback from a range of advocates regarding their experiences with cancer research to identify common themes and to generate hypotheses for future research. Methods: An online survey with 14 questions about the advocates’ background and experiences with research advocacy was distributed in early 2024 to cancer research advocates through multiple organizations and research advocacy networks. Thirty individuals responded, half of whom were advocates with 10+ years of experience. Results: Breast cancer was the most common cancer site of research activity (n=18/30, 60%), and clinical trials (n=29/30, 97%), and translational research (n=25/30, 83%) were the types of research of greatest interest. Respondents were generally enthused about their work and felt like they were making a meaningful contribution. The greatest frustration was being asked for letters of support at the last minute or otherwise “checking a box” for a researcher applying for a grant. Many respondents expressed difficulty in getting connected with research activities, especially at a local level. The advocates noted that the “career path” to becoming an established advocate is not always clear nor is it easy to find opportunities Conclusions and Recommendations: Our survey results demonstrate that research advocates are very engaged and satisfied with their experiences. While excellent training programs provide a solid foundation for new advocates, there should be a greater focus on continued engagement and mentoring for “mid-career” advocates. Citation Format: Bob Riter, Hillary Andrews. Cancer research advocates: satisfaction, frustration, and opportunities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4024.